| Date | Title | Description |
| 18.02.2026 | Newron Pharmaceuticals Secures Up To €38 Million To Advance Phase III Evenamide Program | Newron Pharmaceuticals has secured up to €38 million in gross proceeds through an agreement with a group of existing and new shareholders from Europe and Asia, strengthening its financial position as it advances the Phase III ENIGMA-TRS pro... |
| 18.10.2021 | Newron Pharmaceuticals S p A : Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB) | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing/Miscellaneous
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
18.10.2021 / 17:45
The issuer is solely responsible for the content o... |
| 16.09.2021 | Newron Pharmaceuticals S p A : announces Half-Year 2021 results | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Report
Newron announces Half-Year 2021 results
16.09.2021 / 07:00
The issuer is solely responsible for the content of this announcement.
Newron announces Half-Year 2021 resul... |
| 16.09.2021 | Newron announces Half-Year 2021 results | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Half Year Results Newron announces Half-Year 2021 results 16-Sep-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for... |
| 16.09.2021 | PRESS RELEASE : Newron announces Half-Year 2021 results | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Report Newron announces Half-Year 2021 results 2021-09-16 / 07:00 The issuer is solely responsible for the content of this announcement.
-------------------------------------... |
| 06.09.2021 | Newron Pharmaceuticals S p A : Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
06.09.2021 / 07:00
The issuer is solely responsible for the content of this announc... |
| 06.09.2021 | Newron Pharmaceuticals S p A : Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB) | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
06.09.2021 / 17:45
The issuer is solely responsible for the content of this an... |
| 20.05.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
Newron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA
20.05.2021 / 07:00
The issuer is solely responsible for the content of this announcement.... |
| 04.05.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous
Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA
04-May-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
... |
| 04.05.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA
04.05.2021 / 07:00
The issuer is solely responsible for the content of this announcement.
... |
| 13.04.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces AGM 2021 result | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): AGM/EGM
Newron announces AGM 2021 result
13.04.2021 / 12:00
The issuer is solely responsible for the content of this announcement.
Newron announces AGM 2021 result
Milan, Italy - April... |
| 13.04.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces AGM 2021 result | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous
Newron announces AGM 2021 result
13-Apr-2021 / 12:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the conten... |
| 01.04.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
01.04.2021 / 07:00
The issuer is solely responsible f... |
| 01.04.2021 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
01-Apr-2021 / 07:00 CET/CEST
Release of an ad hoc... |
| 11.08.2020 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals S p A : provides clinical and business update | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
Newron Pharmaceuticals provides clinical and business update
11.08.2020 / 07:00
The issuer is solely responsible for the content of this announcement.
Newron Pharmaceutic... |
| 11.08.2020 | NEWRON PHARMACEUTICALS S.P.A.
Newron Pharmaceuticals provides clinical and business update | Newron Pharmaceuticals provides clinical and business update
All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021
In advanced evalu... |
| 22.05.2016 | Zambon Launches Xadago® (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease | Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with... |
| 22.03.2016 | Evenamide (NW-3509): Evidence of Anti-Psychotic Efficacy as an Add-On to Antipsychotics in Ongoing Phase 2 Study May Suggest an Alternative Approach to the Treatment of Schizophrenia | Newron to present at SIRS Conference
MILAN–(BUSINESS WIRE)–March 23, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous... |
| 22.03.2016 | Newron Shareholders Support Advancing Key CNS Pipeline Projects | All AGM/EGM Motions Accepted by Vast Majorities of Represented Shareholders
MILAN–(BUSINESS WIRE)–March 22, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patien... |
| 16.03.2016 | Zambon and US WorldMeds Partner to Bring Newron Pharmaceuticals’ Parkinson’s Disease Treatment Xadago® (safinamide) to the U.S. | Xadago® (safinamide) is already approved in the EU and Switzerland, under review by the U.S. Food and Drug Administration Drug candidate has potential to assist the more than one million Americans living with Parkinson’s
MILAN–(BUSINESS WIR... |
| 07.03.2016 | Newron Pharmaceuticals to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York | MILAN–(BUSINESS WIRE)–March 7, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), announced that Stefan Weber, the company’s Chief Executive Officer, will present a clinical, commercial and corporate update at the 23rd Annual BioCentury Future... |
| 01.03.2016 | Newron Pharmaceuticals reports 2015 financial results | Board approves agenda for AGM on March 22, 2016
MILAN–(BUSINESS WIRE)–March 1, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the centr... |
| 29.02.2016 | Newron Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases | MILAN–(BUSINESS WIRE)–February 29, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today anno... |
| 26.02.2016 | Newron Pharmaceuticals to Present 2015 Financial Results on March 1, 2016 | MILAN–(BUSINESS WIRE)–February 26, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today anno... |
| 22.02.2016 | Zambon Launches Xadago® (safinamide) in Spain for Patients with Mid- to Late-Stage Parkinson’s Disease | Spain is the third country in which Xadago® is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD)
MILAN–(BUSINESS WIRE)–February 22, 2016–
Zambon S.p.A., an international pharmaceutical company strongly c... |
| 27.01.2016 | Newron Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference in New York | MILAN–(BUSINESS WIRE)–January 27, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Stefan Weber, CE... |
| 07.01.2016 | Newron Pharmaceuticals to Present at the 8th Annual Biotech Showcase Conference in San Francisco | MILAN–(BUSINESS WIRE)–January 7, 2016–
Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Stefan Weber, CEO... |
| 02.12.2015 | Newron Initiates U.S. Phase II Trial in Patients with Schizophrenia | NW-3509 – First voltage-gated sodium channel blocker as add-on therapy for the treatment of schizophrenia
MILAN–(BUSINESS WIRE)–December 2, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel ... |
| 25.11.2015 | Newron Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference | MILAN–(BUSINESS WIRE)–November 25, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Stefan Weber, C... |
| 20.11.2015 | Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund | Financing Supports Clinical Development of Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease
MILAN–(BUSINESS WIRE)–November 20, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company fo... |
| 13.11.2015 | Swissmedic Approves Xadago® (Safinamide) for Use in Parkinson’s Disease | MILAN–(BUSINESS WIRE)–November 13, 2015–
Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and deve... |
| 28.10.2015 | Newron Pharmaceuticals Announces Planned Pivotal Trial Design for Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease | Recognizes Rett Syndrome Awareness Month*
Provides update on early-stage pipeline prioritization
MILAN–(BUSINESS WIRE)–October 28, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central n... |
| 30.09.2015 | Xadago® (safinamide) New Drug Application Late-Cycle Review Meeting Completed with U.S. FDA | MILAN–(BUSINESS WIRE)–September 30, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, and its commercial and development partner, Zambon S.p.... |
| 15.09.2015 | Newron Reports Half-Year 2015 Results | MILAN–(BUSINESS WIRE)–September 15, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a research and development company focused on novel central nervous system (CNS) and pain therapies, today announces its financial results for th... |
| 14.07.2015 | Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome | MILAN–(BUSINESS WIRE)–July 14, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that the U.S. Food and Drug Administration (... |
| 25.06.2015 | Newron Receives Positive Opinion for Orphan Medicinal Product Designation for Sarizotan to Treat Patients with Rett Syndrome from the Committee for Orphan Medicinal Products from the European Medicine... | MILAN–(BUSINESS WIRE)–June 25, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces that it has received a positive opinion for its New Chemical Entity Sarizot... |
| 30.04.2015 | Newron Completes CHF24.3M/US$25.5M in Private Placement from Leading EU and US Investors | MILAN–(BUSINESS WIRE)–April 30, 2015–
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces that it has completed a capital increase raising gross proceeds of CHF24.3... |
| 15.02.2011 | Newron receives EUR 3.7 million under Italian government R&D support program | Milan, Italy, February 15, 2011 – Newron Pharmaceuticals S.p.A. (SIX: NWRN), a research and development company focused on novel CNS and pain therapies, announced today that it has been advised by the Italian government’s Ministero dell’ Is... |
| - | Newron Announces 2020 Financial Results and Provides Outlook For 2021 | MILAN, Italy--(BUSINESS WIRE)--Mar 16, 2021--
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripher... |
